SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. [2395.T]
TOKYO, May 11 (Pulse News Wire) – Shin Nippon Biomedical Laboratories,ltd. (2395.T) reported revenue growth for the fiscal year ending March 2026, reaching -¥330 million, up 1.1% from the previous year.
However, operating profit declined by 3.3%, primarily due to higher expenses related to the commercialization efforts of Satsuma's nasal migraine drug, AtzumiTM. Non-clinical CRO orders increased by 5.8% to reach ¥37.80 billion, driven by robust overseas demand. The company expects continued investment in strategic initiatives such as expanding its non-clinical CRO operations and enhancing facilities like the EU experimental building, which is set to complete in 2027. For the fiscal year ending March 2027, the company forecasts revenue of ¥380 billion, representing a 54.8% increase compared to the previous year.
Operating profit is expected to rise by 3.5% to ¥29.25 billion, despite anticipated higher costs associated with the full-scale launch of the Atzumi project. Additionally, the firm plans to strengthen its workforce and IT infrastructure while advancing digital transformation efforts. In the near term, the company anticipates a significant boost in sales and profits in the first quarter of the upcoming fiscal year, followed by steady performance in subsequent quarters. Notably, the projected lower operating profit for Satsuma is expected to widen by ¥400 million compared to the previous year, reflecting ongoing investments in Atzumi’s development.
🟡 Confidence: Standard AI-translated content.